D. Müller

发表

Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel

D. Müller, A. Maruf, C. Bousman, 2019, Current opinion in psychiatry.

Relation between cerebrospinal fluid, gray matter and white matter changes in families with schizophrenia.

Michael Wagner, Kai Vogeley, Thomas G Schulze, 2006, Journal of psychiatric research.

Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: A case–control study

D. Rujescu, C. Montag, J. Gallinat, 2013, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

E. Corruble, R. Lanzenberger, J. Meyer, 2021, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Review and Consensus on Pharmacogenomic Testing in Psychiatry

Bahareh Behroozi Asl, F. McMahon, L. DeLisi, 2020, Pharmacopsychiatry.

Liver enzyme CYP2D6 gene and tardive dyskinesia.

J. Lieberman, S. Potkin, G. Remington, 2020, Pharmacogenomics.

Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada

K. Aitchison, P. Arnold, D. Müller, 2020, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Opportunities and challenges of implementation models of pharmacogenomics in clinical practice

Lisa C. Brown, D. Müller, C. Bousman, 2020, Personalized Psychiatry.

Genetic testing as a supporting tool in prescribing psychiatric medication: Design and protocol of the IMPACT study.

J. Kennedy, D. Müller, C. Zai, 2018, Journal of psychiatric research.

Psychiatric manifestations of Kleefstra syndrome: a case report

P. Desarkar, Kazunari Yoshida, D. Müller, 2023, Frontiers in psychiatry.

Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults.

Etienne Sibille, Eric J Lenze, Benoit H Mulsant, 2017, The American journal of psychiatry.

The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment

D. Müller, A. Chintoh, V. Marshe, 2018, Front. Neurosci..

Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis

S. Strother, R. Lam, S. Kennedy, 2021, Psychological Medicine.

Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life.

Jeffrey A. Shaman, B. Mulsant, C. Reynolds, 2018, Pharmacogenomics.

Physicians' opinions following pharmacogenetic testing for psychotropic medication

J. Kennedy, D. Müller, E. Brandl, 2015, Psychiatry Research.

Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations

J. Lieberman, S. Potkin, T. Shinkai, 2005, Psychopharmacology.

Overview: Towards individualized treatment in schizophrenia

J. Kennedy, D. Müller, V. De Luca, 2003 .

A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia

J. Lieberman, Deepika Singh, H. Meltzer, 2010, Neuropsychopharmacology.

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy

K. Sangkuhl, T. Klein, G. Ruaño, 2021, Clinical pharmacology and therapeutics.

The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain

J. Lieberman, S. Kennedy, H. Meltzer, 2015, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis

Lisa C. Brown, D. Müller, Lisa C Brown, 2022, The Pharmacogenomics Journal.

Family and case–control association study of the tumor necrosis factor-alpha (TNF-α) gene with schizophrenia and response to antipsychotic medication

J. Lieberman, P. Czobor, J. Volavka, 2006, Psychopharmacology.

Genetics of antipsychotic drug outcome and implications for the clinician: into the limelight

D. Müller, J. Pouget, T. Shams, 2014 .

Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment

A. Grace, G. Remington, Y. Hirano, 2022, Molecular Psychiatry.

Regulation of melanocortin-4-receptor (MC4R) expression by SNP rs17066842 is dependent on glucose concentration

J. Kennedy, D. Müller, C. Zai, 2020, European Neuropsychopharmacology.

Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications

S. Kennedy, D. Müller, T. Fonseka, 2016, Molecular Neuropsychiatry.

Association of the MTHFR gene with antipsychotic-induced metabolic abnormalities in patients with schizophrenia.

D. Müller, M. Kuzman, D. Müller, 2012, Pharmacogenomics.

Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis

J. Lieberman, S. Potkin, H. Meltzer, 2016, The international journal of neuropsychopharmacology.

Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature

D. Müller, M. Richter, T. Fonseka, 2014, Current Psychiatry Reports.

Association between the DAOA/G72 gene and bipolar disorder and meta-analyses in bipolar disorder and schizophrenia.

T. Shinkai, J. Kennedy, D. Müller, 2011, Bipolar disorders.

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia

J. Lieberman, W. Honer, P. Czobor, 2005, Neuroscience Letters.

Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical Trials

Lisa C. Brown, D. Müller, A. Maruf, 2022, Clinical pharmacology and therapeutics.

Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis

J. Bishop, D. Müller, A. Maruf, 2021, Journal of personalized medicine.

Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.

Annette Lee, P. Gregersen, R. Ophoff, 2012, Archives of general psychiatry.

HTR2C haplotypes and antipsychotics‐induced weight gain: X‐linked multimarker analysis

J. Lieberman, J. Volavka, H. Meltzer, 2007, Human psychopharmacology.

Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain

J. Lieberman, H. Meltzer, J. Kennedy, 2018, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Genetics of antipsychotic-induced weight gain: update and current perspectives.

D. Müller, A. Kao, D. Müller, 2013, Pharmacogenomics.

Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis.

J. Lieberman, H. Meltzer, J. Kennedy, 2010, Pharmacogenomics.

Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study

G. Remington, A. Karnovsky, P. Gerretsen, 2023, Frontiers in Psychiatry.

Genetics of antipsychotic treatment emergent weight gain in schizophrenia.

J. Kennedy, D. Müller, J. Kennedy, 2006, Pharmacogenomics.

Recent advances in genetics of bipolar disorder

J. Kennedy, D. Müller, J. Kennedy, 2005 .

PharmGKB summary: carbamazepine pathway

R. Altman, J. Kelsoe, C. Thorn, 2011, Pharmacogenetics and genomics.

GWAS-based machine learning approach to predict duloxetine response in major depressive disorder.

Anne-Christin Hauschild, Joseph Geraci, Jane A Foster, 2018, Journal of psychiatric research.

Systematic review of mitochondrial genetic variation in attention-deficit/hyperactivity disorder

D. Müller, V. Gonçalves, James L. Kennedy, 2022, European Child & Adolescent Psychiatry.

Antidepressant-Associated Mania in Bipolar Disorder: A Review and Meta-analysis of Potential Clinical and Genetic Risk Factors.

J. Kennedy, D. Müller, C. Zai, 2020, Journal of clinical psychopharmacology.

Neurexin-1 and Frontal Lobe White Matter: An Overlapping Intermediate Phenotype for Schizophrenia and Autism Spectrum Disorders

Jason P. Lerch, Aristotle N. Voineskos, Arun K. Tiwari, 2011, PloS one.

ANK3, CACNA1C and ZNF804A gene variants in bipolar disorders and psychosis subphenotype

T. Lett, D. Müller, C. Zai, 2011, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain

J. Lieberman, S. Potkin, H. Meltzer, 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Economic evaluation in psychiatric pharmacogenomics: a systematic review

P. Papantoniou, G. Patrinos, D. Müller, 2021, The Pharmacogenomics Journal.

The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies

D. Müller, M. Khorshidi, A. Saedisomeolia, 2020, European Journal of Nutrition.

Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions.

B. Mulsant, C. Reynolds, E. Lenze, 2020, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response

S. Kennedy, G. MacQueen, B. Frey, 2021, Translational Psychiatry.

KIBRA Polymorphism Is Associated with Individual Differences in Hippocampal Subregions: Evidence from Anatomical Segmentation using High-Resolution MRI

Adam K. Anderson, Brian Levine, Rebecca M. Todd, 2013, The Journal of Neuroscience.

Clinical implications of APOE genotyping for late-onset Alzheimer’s disease (LOAD) risk estimation: a review of the literature

D. Müller, V. Marshe, Ilona Gorbovskaya, 2018, Journal of Neural Transmission.

Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response

B. Mulsant, C. Reynolds, R. Lam, 2021, Translational Psychiatry.

Pharmacogenetics of antipsychotic-induced weight gain.

P. Muglia, J. Kennedy, D. Müller, 2004, Pharmacological research.

The catechol-O-methyl-transferase gene in tardive dyskinesia

J. Lieberman, S. Potkin, G. Remington, 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Pharmacogenetics of tardive dyskinesia: an updated review of the literature.

D. Müller, C. Zai, Rachel Lanning, 2016, Pharmacogenomics.

Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications

D. Müller, Kazunari Yoshida, D. Müller, 2018, Molecular Neuropsychiatry.

The role of the ITIH3 rs2535629 variant in antipsychotic response

S. Potkin, H. Meltzer, J. Kennedy, 2016, Schizophrenia Research.

Towards precision medicine in generalized anxiety disorder: Review of genetics and pharmaco(epi)genetics.

J. Kennedy, D. Müller, M. Richter, 2019, Journal of psychiatric research.

Identifying the Common Genetic Basis of Antidepressant Response

M. Rietschel, W. Maier, B. Mulsant, 2021, Biological psychiatry global open science.

Exploring brain connectivity changes in major depressive disorder using functional‐structural data fusion: A CAN‐BIND‐1 study

Jacqueline K. Harris, Gesine L. Alders, S. Strother, 2021, Human brain mapping.

Genes for Emotion-Enhanced Remembering Are Linked to Enhanced Perceiving

A. Anderson, B. Levine, D. Lee, 2013, Psychological science.

Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study

J. Lieberman, H. Meltzer, D. Müller, 2023, The Pharmacogenomics Journal.

Reviewing pharmacogenetics to advance precision medicine for opioids.

D. Müller, B. Le Foll, R. Jhirad, 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: Update and report from a pharmacogenetic service clinic

D. Müller, E. Brandl, I. Kekin, 2013, International review of psychiatry.

Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report

S. Strother, R. Lam, S. Kennedy, 2021, Psychoneuroendocrinology.

International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic)

G. Kirov, N. Craddock, P. Sullivan, 2019, European Archives of Psychiatry and Clinical Neuroscience.

Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine

J. Lieberman, S. Potkin, G. Remington, 2016, Molecular Neuropsychiatry.

Pharmacogenetics of Antipsychotics

J. Kennedy, D. Müller, E. Brandl, 2014, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report

Jacqueline K. Harris, S. Strother, R. Lam, 2020, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols

Stephen C. Strother, Stephen R. Arnott, Catherine Lebel, 2019, Journal of psychiatry & neuroscience : JPN.

Antipsychotic Induced Weight Gain: Genetics, Epigenetics, and Biomarkers Reviewed

D. Müller, T. Shams, D. Müller, 2014, Current Psychiatry Reports.

MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes

C. Lewis, H. Feilotter, E. Nestler, 2017, Nature Communications.

Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort

Stephen C. Strother, Moyez Dharsee, Luciano Minuzzi, 2016, BMC Psychiatry.

Akt2 Gene is Associated with Anxiety and Neuroticism in Humans

J. Beck, J. Gallinat, S. Borgwardt, 2014 .

Cognitive and psychosocial function in retired professional hockey players

C. Esopenko, B. Levine, J. Kennedy, 2017, Journal of Neurology, Neurosurgery & Psychiatry.

Investigation of the human serotonin 6 [5-HT6] receptor gene in bipolar affective disorder and schizophrenia.

S. Cichon, M. Rietschel, M. Nöthen, 2000, American journal of medical genetics.

Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients

J. Lieberman, S. Potkin, G. Remington, 2009, The Pharmacogenomics Journal.

The pharmacogenetics of antipsychotic-induced adverse events

D. Müller, C. Zai, N. Chowdhury, 2013, Current opinion in psychiatry.

Association study of polymorphisms in Insulin Induced Gene 2 (INSIG2) with antipsychotic‐induced weight gain in European and African‐American schizophrenia patients

J. Lieberman, H. Meltzer, J. Kennedy, 2010, Human psychopharmacology.

Pharmacogenetics of alcohol, nicotine and drug addiction treatments

A. Heinz, J. Kennedy, T. George, 2011, Addiction biology.

PW01-54 - Correlation Of A Set Of Gene Variants, Life Events And Personality Features On Adult Adhd Severity

A. Serretti, L. Mandelli, J. Kennedy, 2010, European Psychiatry.

Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report

R. Lam, S. Kennedy, B. Frey, 2021, CNS Drugs.

Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia

J. Lieberman, S. Potkin, G. Remington, 2008, Schizophrenia Research.

No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain

J. Lieberman, H. Meltzer, D. Müller, 2014, Psychiatry Research.

Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update

D. Müller, V. Sriretnakumar, Eric Huang, 2015, Expert opinion on drug metabolism & toxicology.

Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain.

J. Lieberman, H. Meltzer, D. Müller, 2014, Pharmacogenomics.

Exploratory study on association of genetic variation in TBC1D1 with antipsychotic‐induced weight gain

J. Lieberman, H. Meltzer, J. Kennedy, 2013, Human psychopharmacology.

Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients

J. Lieberman, H. Meltzer, J. Kennedy, 2013, Journal of clinical psychopharmacology.

Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder

J. Kennedy, D. Müller, J. Strauss, 2006, British Journal of Psychiatry.

Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients

J. Lieberman, H. Meltzer, D. Müller, 2010, Progress in Neuro-psychopharmacology and Biological Psychiatry.

Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain.

J. Lieberman, H. Meltzer, J. Kennedy, 2012, Journal of psychiatric research.

Suggestive association between the C825T polymorphism of the G-protein β3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia

J. Lieberman, P. Czobor, J. McEvoy, 2005, European Neuropsychopharmacology.

Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans

H. Meltzer, J. Kennedy, E. Nurmi, 2019, Schizophrenia Research.

Association between Oxytocin Receptor Gene Polymorphisms and Self-Rated ‘Empathic Concern’ in Schizophrenia

Jürgen Gallinat, Daniel J. Müller, D. Rujescu, 2012, PloS one.

Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.

D. Müller, F. Islam, Ilona Gorbovskaya, 2021, Advances in experimental medicine and biology.

The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism.

J. Lieberman, J. Kennedy, D. Müller, 2012, Genetic testing and molecular biomarkers.

PharmGKB summary: clozapine pathway, pharmacokinetics

Russ B. Altman, Teri E. Klein, Caroline F. Thorn, 2018, Pharmacogenetics and genomics.

Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response.

J. Lieberman, S. Potkin, H. Meltzer, 2016, Pharmacogenomics.

Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder.

S. Kennedy, J. Kennedy, S. Rotzinger, 2015, Pharmacogenomics.

Pharmacogenomic Testing for Neuropsychiatric Drugs: Current Status of Drug Labeling, Guidelines for Using Genetic Information, and Test Options

J. Bishop, D. Müller, K. Drozda, 2014, Pharmacotherapy.

Analysis of 34 candidate genes in bupropion and placebo remission.

J. Kennedy, T. Arenovich, D. Müller, 2013, The international journal of neuropsychopharmacology.

Submission Category: Regular Research Article Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis.

S. Potkin, H. Meltzer, B. Crespo-Facorro, 2016 .

Pharmacogenetics of obsessive-compulsive disorders.

D. Müller, E. Brandl, M. Richter, 2012, Pharmacogenomics.

Human Neuroscience Hypothesis and Theory Article the Uncanny Return of the Race Concept

S. Krach, D. Müller, A. Heinz, 2022 .

Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.

R. Lam, S. Kennedy, G. MacQueen, 2020, The Journal of clinical psychiatry.

Association between a polymorphism in the pseudoautosomal X-linked gene SYBL1 and bipolar affective disorder.

S. Cichon, M. Rietschel, M. Nöthen, 2002, American journal of medical genetics.

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

M. Whirl‐Carrillo, T. Klein, B. Carleton, 2018, Clinical pharmacology and therapeutics.

Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process

Teri E. Klein, Vojtech Huser, Michelle Whirl-Carrillo, 2014, Current drug metabolism.

The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment

D. Müller, Ilona Gorbovskaya, M. Hahn, 2021, Nutrients.

Genetics of Common Antipsychotic-Induced Adverse Effects

Raymond R. MacNeil, D. Müller, D. Müller, 2016, Molecular Neuropsychiatry.

Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans.

J. Lieberman, H. Meltzer, J. Kennedy, 2009, Pharmacogenomics.

Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report

Jacqueline K. Harris, S. Strother, S. Kennedy, 2021, Translational Psychiatry.